top of page

 Unlock Growth in
Rare Disease Markets

AI-powered strategy to launch faster, reduce risk, and outperform industry benchmarks

Fractional 
Leadership
Deep Domain
Expertise
De-risk Commercialization

 
Clarity AI HITL Commercial Workflow 
Experienced Leadership
Team

Bridging Gaps for Growth in the Rare Disease Industry

Top Rare Disease Industry Challenges

​Your orphan drug has breakthrough clinical data and FDA approval—but faces these critical execution and strategic challenges:

  • Exclusivity windows closing, demanding lifecycle extensions and new indications

  • US-only approvals limiting global reach and revenue potential

  • Small commercial teams lacking payer, market-access, and field-force expertise

  • Niche patient populations requiring compelling differentiation and real-world evidence

  • Single-product concentration risk exposing companies to market volatility

  • Fragmented partnerships and licensing struggles with Big Pharma

  • Investor pressure for rapid milestones, disciplined burn, and demonstrable ROI

​​

rare disease

How We Deliver Measurable Outcomes

.

1. Lifecycle Management & Portfolio Diversification

  • Identify and validate new indications and line extensions to maximize remaining exclusivity

  • Pursue international approvals (Health Canada, EMA) to unlock incremental markets

  • Structure licensing-in of complementary assets and alliances to spread risk and build a multi-product pipeline

 

2. Global Market-Access & GTM Excellence

  • Phased, data-driven launch across US, Canada, and Europe—aligning regulatory filings, HTA submissions, and distribution partnerships

  • Value-Based Contracting and HEOR modeling to justify pricing in small markets and secure reimbursement

  • Build-Operate-Transfer commercial infrastructure: fractional leadership, right-sized sales forces, specialty-pharmacy alignment, and end-to-end campaign execution

 

3. Evidence-Backed Differentiation

  • Deploy patient registries and real-world data to substantiate comparative effectiveness

  • Craft payer narratives and economic dossiers showcasing clinical benefit and cost offsets

  • Engage KOLs early in advisory boards to co-create evidence and drive peer advocacy

 

4. Strategic Partnerships & Licensing

  • Negotiate win-win licensing deals with Big Pharma or biotech partners, optimizing upstream and downstream value

  • Identify and onboard global distribution partners with established channel expertise

  • Leverage PAG alliances for registry support, advocacy, and patient engagement

 

5. Investor-Grade ROI Focus

  • 43% faster time-to-market—capturing revenue during critical exclusivity windows

  • 60-point reduction in commercialization risk via predictive analytics and de-risking frameworks

  • Clear milestone-driven execution plans aligning with VC expectations for burn discipline and early revenue​

Why Strategic Growth AI

.

Strategic Growth AI Differentiators

​

  • Clarity AI™ Platform:

    • AI-powered patient and stakeholder mapping, predictive market-access modeling, and launch-trajectory forecasting

  • Embedded Execution

    • Fractional C-suite, BOTO commercial build-operate-transfer model, and weekly KPI-driven sprints, delivering capability, not just advice

  • Global with Local Nuance:

    • Former FDA, Health Canada, EMA reviewers; payer intelligence across US, Canada, Europe; culturally attuned stakeholder engagement

 

Ready to Transform Rare Disease Commercialization?

 

Schedule your Strategic Growth Assessment and discover how we turn execution gaps into scalable, payer-backed success, ensuring your innovation reaches every patient, in every market, with measurable ROI.​

Professional Networks

UBC Entrepreneurship   • BC Tech   • AIinBC   • Life Sciences BC

bottom of page